The field of sexual medicine continues to evolve, and bremelanotide is at the forefront of that evolution, bringing us closer to truly holistic treatment of sexual dysfunction
Clinical observations from patients treated with GLP1 receptor agonists for Type 2 diabetes suggest that GLP1 receptor agonists may reduce body weight more in subjects with higher baseline body mass index (Niswender et al., 2013), so, in future clinical trials, it may be useful to evaluate the effects of GLP1 receptor agonists on alcohol intake in more specific subgroups of AUD patients, for example, in AUD patients with comorbid obesity
P., Meyyappan G
[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Rossi F., Tortora C., Punzo F., Bellini G., Argenziano M., Di Paola A., Torella M., Perrotta S
[Google Scholar] 15.Vasiljevski E.R., et al